医学
血小板生成素
造血干细胞移植
内科学
血小板
骨髓增生异常综合症
再生障碍性贫血
血小板输注
胃肠病学
队列
移植
造血
干细胞
肿瘤科
免疫学
骨髓
生物
遗传学
作者
Hong Wang,Man Huang,Ying Zhao,Jiaqian Qi,Chun Chen,Yaqiong Tang,Huiying Qiu,Chengcheng Fu,Xiaowen Tang,Depei Wu,Changgeng Ruan,Yue Han
标识
DOI:10.1016/j.bbmt.2017.06.010
摘要
Poor platelet graft function (PPGF) is a significant complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). However, no optimal treatment has been recommended. This study investigated aspects of platelet recovery after allo-HSCT, including prognostic value and the effect of recombinant human thrombopoietin (rhTPO). We retrospectively analyzed 275 patients who received allo-HSCT in our center. Of them, 135 (49.1%) patients had good platelet graft function (GPGF) and 140 (50.9%) had PPGF. The latter included 59 (21.5%) patients with primary PPGF and 81 (29.4%) with secondary PPGF. Multivariate analysis showed that male gender (P = .024), lower CD34+ cell count (P = .04), and no use of rhTPO (P <.001) were associated with PPGF. The 3-year overall survival rate of patients with PPGF (58%) was significantly less than that of patients with GPGF (82%; P <.001). We further analyzed the effect of rhTPO on prognosis of patients after allo-HSCT. Although no advantage was apparent when analyzing the entire cohort, for patients with myelodysplastic syndromes and aplastic anemia, rhTPO was associated with a significant survival advantage (P = .014).
科研通智能强力驱动
Strongly Powered by AbleSci AI